MDR Reform at Year-End: What’s Coming?
The EU Medical Device Regulation (MDR), adopted in 2017, was designed to strengthen patient safety, traceability, and transparency. Its implementation, however, has also created significant operational pressure for manufacturers, notified bodies, regulators, and healthcare providers.
Calls for targeted reform have focused on a practical question: how can Europe preserve high safety standards while making the regulatory system more predictable, proportionate, and workable?

The central challenge is not whether patient safety should remain the priority. It is whether the current system can deliver that safety without unnecessary delays, inconsistent procedures, or reduced access to important medical devices.
Five Pressures Driving the Call for Change
1. Inconsistent Interpretation and Coordination
Manufacturers can encounter different interpretations and working practices across national authorities and notified bodies. Greater alignment would make planning more reliable and reduce avoidable duplication.
2. Repeated Transitional Extensions
Extensions have helped prevent sudden market disruption, but repeated deadline changes have also made long-term regulatory and product planning more difficult. Businesses need clearer timelines and a more stable path to compliance.
3. Digital and Guidance Gaps
EUDAMED has been introduced in phases, while guidance continues to evolve. Until systems, procedures, and expectations are fully aligned, stakeholders may face uncertainty about documentation, registration, and post-market responsibilities.

4. Pressure on Device Availability
Higher certification costs and complex requirements can make some products commercially difficult to maintain, particularly for smaller manufacturers or lower-volume devices. The concern is that regulatory burden may contribute to narrower product portfolios and reduced patient access.
5. Reduced Appeal for Innovation
Long and uncertain certification pathways can influence where companies choose to launch new technologies. A more proportionate framework could help Europe remain attractive for responsible medical device innovation while maintaining robust oversight.

What Targeted MDR and IVDR Revision Could Address
The aim of targeted revision is generally understood to be simplification and greater predictability, not a retreat from patient safety. The most important areas under discussion include:
Reducing Administrative Burden
Removing duplicated or low-value reporting requirements could help organizations, particularly SMEs, focus resources on activities that contribute most directly to quality and safety.

Improving Certification Predictability
More consistent notified body practices, clearer service expectations, and better visibility into review timelines could make CE-marking projects easier to plan.

Applying Requirements in Proportion to Risk
A more risk-based approach could ensure that lower-risk products do not face the same level of scrutiny and cost as high-risk devices, while preserving appropriate controls for each category.

Accelerating Digitalization
Greater use of electronic instructions for use, structured digital submissions, and fully integrated EUDAMED processes could reduce paperwork and improve information exchange.
Simplifying Governance
Clearer responsibilities and more efficient procedures for approvals, updates, and compliance activities could reduce bottlenecks across the system.
Supporting International Alignment
Closer cooperation with international regulatory partners could reduce unnecessary barriers for manufacturers serving multiple markets, without lowering EU safety expectations.

Coordinating with Other EU Legislation
Medical device requirements increasingly interact with cybersecurity, data, sustainability, and other EU rules. Better coordination can help businesses avoid conflicting or overlapping obligations.
The objective is a regulatory system that remains rigorous while becoming clearer, more proportionate, and easier to navigate.
The 2025 Consultation in Context

The European Commission conducted a consultation on targeted revision of the MDR and IVDR, with feedback closing on October 6, 2025. That process gave manufacturers, healthcare stakeholders, regulators, and other interested parties an opportunity to share evidence and recommendations.
The original consultation page remains useful as background:
European Commission: targeted revision of EU medical device and IVD rules
What Distributors and Manufacturers Should Do Now

Regardless of the final form of reform, businesses can strengthen their readiness by focusing on actions that remain valuable under any regulatory scenario:
- Review product portfolios and identify certification or renewal risks early.
- Maintain clear technical documentation and post-market evidence.
- Confirm responsibilities across manufacturers, importers, distributors, and Authorized Representatives.
- Monitor official European Commission and MDCG updates.
- Build realistic timelines for notified body engagement and market access.
Collaboration Will Remain a Competitive Advantage

Regulatory change creates both pressure and opportunity. Distributors that work closely with manufacturers, regulatory specialists, and market partners will be better positioned to manage documentation, registration, product updates, and market communication.
Strong cooperation can also support faster issue resolution, more transparent planning, and better long-term decisions about which products to introduce or maintain in the EU market.
Prepare for Regulatory Change with the Right Partner
MedAsia supports global partners with product sourcing, documentation coordination, compliance communication, and market preparation.
Contact MedAsiaWE RECOMMEND
Related posts
- Subscribe MedInsights
- Subscribe MedInsights
- Subscribe MedInsights
- Subscribe MedInsights
- Subscribe MedInsights
